Vous avez cherché: spds (Danois - Anglais)

g bstformand i spds landsråd.
q vice-chairman of the spd federal council.

° signifikant associeret med extaviabehandling for spds, p<0,05
° significantly associated with extavia treatment for spms, p <0.05

g medlem af forbundsdagen 1972-1980, næstformand for spds gruppe 1976.
vice-chairman of the spd parliamentary party in the bundestag 1976.

g medlem af spds landsråd; formand for spds gruppe i gudensbergs kommunalbestyrelse.
g member of the spd federal council; chairman of spd group on gudensberg municipal council.

g medlem af den bayerske landdag 1966-1980, ordfører for spds gruppe i forbrugerspørgsmål.
gsocialist group whip on the ep commit­tee on the environment, public health and consumer protection 19791984.

i de politiske partiers programmer (undtagen spds orienteringsramme for 1975-1985).
7 as a minor sphere of economic and social policy.

g medlem af byrådet i dortmund 1969-1979, formand for skoleudvalget, næstformand for spds gruppe.
q member of dortmund city council 1969-1979; chairman of the education committee; vice-chairman of the socialist group.

g medlem af spd 1954; formand for spd i franken 1970; medlem af spds hovedbestyrelse siden 1973.
g member of the spd 1954; district chairman of the spd in franconia 1970. member of the federal directorial committee since 1973.

medlem af bestyrelsen for spd i ostwestfalen-lippe 1974-1982. medlem af spds landsråd siden 1980.
g member of the spd since 1970; held various offices in the young socialists; vice­chairman, bad lippspringe branch 1973; member, paderborn­büren sub­district spd directorial committee since 1972; sub­district vice­chairman 1981 ; member, ostwestfalen­lippe district spd directorial committee 1974­1982; member, spd party council since 1980.

signifikant associeret med beraferon- behandling hos patienter med første hændelse, som tyder på dissemineret sklerose, p < 0, 05 * signifikant associeret med betaferon- behandling for rrds, p < 0, 05 ° signifikant associeret med betaferon- behandling for spds, p < 0, 05 § reaktioner på injektionsstedet (forskellige typer) omfatter alle uønskede bivirkninger, som forekommer på injektionsstedet, dvs. følgende termer: blødning på injektionsstedet, overfølsomhed på injektionsstedet, inflammation på injektionsstedet, absces på injektionsstedet, nekrose på injektionsstedet, smerte på injektionsstedet, reaktion på injektionsstedet, ødem på injektionsstedet og atrofi på injektionsstedet & ” influenzalignende systemkompleks ” omfatter influenzasyndrom og/ eller en kombination af mindst to bivirkninger af feber, kulderystelser, myalgi, utilpashed, perspiration. # der blev ikke observeret nogen ændring i den kendte risikoprofil for betaferon under det tredje benefit- studieår.
significantly associated with betaferon treatment for patients with first event suggestive of ms, p < 0.05 * significantly associated with betaferon treatment for rrms, p < 0.05 ° significantly associated with betaferon treatment for spms, p < 0.05 § injection site reaction (various kinds) comprises all adverse events occurring at the injection site, i. e. the following terms: injection site hemorrhage, injection site hypersensitivity, injection site inflammation, injection site mass, injection site necrosis, injection site pain, injection site reaction, injection site edema, and injection site atrophy & “ flu-like symptom complex ” denotes flu syndrome and/ or a combination of at least two aes from fever, chills, myalgia, malaise, sweating. # during the third year of the benefit study, no change of the known risk profile of betaferon was observed.